A case of synchronous relapse of breast cancer and uterine müllerian adenosarcoma post tamoxifen in a premenopausal woman

Purpose & Methods: We report a case of a 42-year-old multigravida, premenopausal woman with breast carcinoma, who presented after four years of use of adjuvant tarnoxifen with synchronous liver, bone, and lung metastasis of breast cancer with mullerian adenosarcoma. Results: Immunohistochemical stains on the uterine tumor for estrogen and progesterone receptors showed positivity for both epithelial and stromal cells, actin, and desmin while the proliferative index (MIB-1) showed positivity for stromal cells only. The patient underwent a hysterectomy followed by palliative chemotherapy. She died 14 months after her relapse because of progressive disease (cerebral, bone, liver and lung metastases). Conclusion: Our case is the only one reported in the literature with synchronous relapse of breast adenocarcinoma and a Mullerian adenosarcoma. Moreover, it is one of the rare cases occurring in a premenopausal woman since all except two cases were postmenopausal.

Premenopausal, Müllerian adenosarcoma, Relapse, Tamoxifen, Uterine

[1] Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M. et al.: “Tamoxifen for the prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study”. J. Natl. Cancer Inst., 1998, 90, 1371.

[2] Van Leeuwen F., Benraadt J., Coebergh J.W., Kiemeney L.A., Gimbrere C.H., Otter R. et al.: “Risk of endometrial cancer after tamoxifen treatment of breast cancer”. Lancet, 1994, 343, 448.

[3] Fornander T., Rutqvist L.E., Cedermark B., Glas U., Mattsson A., Silfversward C. et al.: “Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers”. Lancet, 1989, 1, 117.

[4] Clement P.B., Scully R.E.: “Müllerian adenosarcoma of the uterus: a clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor”. Cancer, 1974, 34, 1138.

[5] Bocklage T., Lee Kr., Belinson J.L.: “Uterine müllerian adenosarcoma following adenomyoma in a woman on tamoxifen therapy”. Gynecol. Oncol., 1992, 44, 104.

[6] Clement P.B., Oliva E., Young R.H.: “Müllerian adenosarcoma of the uterine corpus associated with tamoxifen therapy: a report of six cases and a review of tamoxifen-associated endometrial lesions”. Int. J. Gynecol. Pathol., 1996, 15, 222.

[7] Carvalho F.M., Carvalho J.P., Motta E.V., Souen J.: “Müllerian adenosarcoma of the uterus with sarcomatous overgrowth following tamoxifen treatment for breast cancer”. Rev. Hosp. Clin. Fac. Med Sao Paulo, 2000, 55, 17.

[8] Arici D.S., Aker H., Yildiz E., Tasyurt A.: “Müllerian adenosarcoma of the uterus associated with tamoxifen therapy”. Arch. Gynecol. Obstet., 2000, 264, 105.

[9] Jessop F.A., Roberts P.F.: “Müllerian adenosarcoma of the uterus in association with tamoxifen therapy”. Histopathology, 2000, 36, 91.

[10] Mhawech P., Vlastos A.T., Pelte M.F.: “Pathologic quiz case. Uterine polypoid mass in post menopausal patient following tamoxifen treatment for breast cancer”. Arch. Pathol. Lab. Med., 2002, 126, 1125.

[11] Martin-Loeches M., Rius J., Orti R.M.: “Uterine sarcoma associated with tamoxifen use: case report”. Eur. J. Gynecol. Oncol., 2003, 24, 202.

[12] Bernstein L., Deapen D., Cerhan J.R., Schwartz S.M., Liff J., McGann-Maloney E. et al.: “Tamoxifen therapy for breast cancer and endometrial cancer risk”. J. Natl. Cancer Inst., 199, 91, 1654.